Josef S. Smolen

Papers

Total Citations

677

H-Index

About

Josef S. Smolen is a leading figure in rheumatology and autoimmune disease research, with a career spanning over four decades. His work has fundamentally shaped our understanding and treatment of rheumatoid arthritis (RA) and other inflammatory conditions. Smolen’s key contributions include pioneering the development of autoantigen microarrays, a high-throughput technology that revolutionized the characterization of autoantibody responses—a breakthrough detailed in his highly cited 2002 paper (677 citations). He is also renowned for defining the "treat-to-target" strategy in RA management, which has become a global standard, emphasizing early, aggressive intervention to achieve remission. His research has been instrumental in the clinical development of biologic therapies, including anti-TNF agents and JAK inhibitors, directly improving patient outcomes. With over 1,000 publications and an h-index exceeding 150, Smolen’s impact is immense; his work has been cited more than 100,000 times. He has received numerous accolades, including the European League Against Rheumatism (EULAR) Prize and the Carol Nachman Award, and served as president of EULAR. For students and researchers, Smolen’s legacy offers a masterclass in translating mechanistic insights into transformative clinical practice.